GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Compass Therapeutics
The stock of Compass Therapeutics, an oncology biotech, reflects the potential of its antibody portfolio. The price chart is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - Oncology immuno-therapy
Compass Therapeutics is a biopharmaceutical company developing antibodies for cancer immunotherapy. We classify it as part of the "Immuno-oncology" segment, one of the most promising areas in the fight against cancer. The chart below shows the overall dynamics of this high-tech and competitive sector.
Broad Market Index - GURU.Markets
Compass Therapeutics is a biopharmaceutical company developing bispecific antibodies for the treatment of oncology and immunological diseases. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the broader market.
Change in the price of a company, segment, and market as a whole per day
CMPX - Daily change in the company's share price Compass Therapeutics
For Compass, a biopharmaceutical company, change_co is a measure of reaction to clinical and regulatory news. Daily fluctuations reflect the volatility associated with the development of immuno-oncology drugs. This metric is a key element for biotech company analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
Compass Therapeutics, Inc. is an oncology company. This chart highlights the extreme volatility of the biotech sector. Comparison with CMPX's performance, which is dependent on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Compass Therapeutics is a biopharmaceutical company developing immunotherapies for the treatment of cancer. Immuno-oncology is a highly volatile and rapidly growing sector. The chart below reflects the average fluctuations in this sector, helping to assess the risks and performance of Compass stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Compass Therapeutics
Compass is a biotech company developing cancer immunotherapy drugs. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
Compass Therapeutics, Inc. is a clinical-stage biotech company developing immunotherapy for cancer. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Compass Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Compass Therapeutics
ProFrac, an oilfield services company specializing in hydraulic fracturing, has monthly fluctuations that directly reflect shale production activity. Demand for its services depends on oil and gas prices and the investment plans of producing companies.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Compass Therapeutics is a biotech company developing antibodies for immuno-oncology. Its goal is to create drugs that can help more patients fight cancer. The biotech sector's performance reflects the overall level of investor optimism regarding this complex yet promising field. The chart below provides the backdrop against which Compass demonstrates its worth.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Compass Therapeutics is a biotech company developing immuno-oncology drugs. Its future depends on the success of clinical trials. The overall market chart provides only background information, while Compass's performance is driven by development news, which can trigger sharp movements counter to any market trend, as is typical in the biotech sector.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Compass Therapeutics
Compass Therapeutics, a biotech company focused on immuno-oncology, exhibits high volatility. Its weekly stock price is a barometer of news about clinical trials and partnerships in this competitive field.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Compass Therapeutics operates in the highly competitive immuno-oncology sector, where investor sentiment drives broad trends. Any significant success or failure in the industry impacts everyone's risk appetite. The chart will show whether CMPX is following the general flow of biotech speculation or whether its unique scientific news is creating its own trend.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
As an early-stage biotech, Compass Therapeutics often ignores broader market trends. Its fate depends not on GDP or inflation, but on clinical trial results. The chart below clearly demonstrates how CMPX shares can live a life of their own, separate from the broader market.
Market capitalization of the company, segment and market as a whole
CMPX - Market capitalization of the company Compass Therapeutics
Compass Therapeutics' market capitalization dynamics reflect a focused bet on immuno-oncology. This biotech company's chart reflects investor expectations for its portfolio of antibodies designed to stimulate the immune system in the fight against cancer. Its volatility is a direct consequence of news about the progress of clinical trials.
CMPX - Share of the company's market capitalization Compass Therapeutics within the market segment - Oncology immuno-therapy
Compass Therapeutics is a biopharmaceutical company developing antibodies for immuno-oncology therapy. Its market share in its niche segment reflects the market's valuation of its scientific platform and pipeline of candidates. The chart below shows how its weighting changes based on clinical trial results.
Market capitalization of the market segment - Oncology immuno-therapy
Compass Therapeutics develops immuno-oncology drugs to stimulate the immune system to fight cancer. The chart below shows the market capitalization of this cutting-edge biotech sector. Its dynamics reflect the hopes for the development of a new generation of cancer drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
Compass Therapeutics is a biotech company working in the field of immuno-oncology, developing antibodies to stimulate the immune system against cancer. The company's market capitalization is determined by its scientific platform and the potential of its candidates. Industry-wide, its value reflects belief in new approaches to treating the most complex forms of cancer.
Book value capitalization of the company, segment and market as a whole
CMPX - Book value capitalization of the company Compass Therapeutics
Compass Therapeutics' book value represents scientific capital for the fight against cancer. It consists of patents for its portfolio of immuno-oncology antibodies, laboratory equipment, and, most importantly, cash for funding clinical trials. The chart below shows how the biotech company uses its capital to advance its research to patients.
CMPX - Share of the company's book capitalization Compass Therapeutics within the market segment - Oncology immuno-therapy
Compass Therapeutics, a biopharmaceutical company, conducts research in its laboratories. These research centers are its primary tangible asset. The S_BCap_Seg graph shows how its share of research infrastructure compares to other players in the immuno-oncology sector.
Market segment balance sheet capitalization - Oncology immuno-therapy
Biotechnology is a world of contrasts. The graph shows the massive factories of pharmaceutical giants. Compass Therapeutics, as a development company, has a more streamlined model. Its value lies in its intellectual property, not in the scale of production that is typical of the R&D stage.
Book value of all companies included in the broad market index - GURU.Markets
Compass Therapeutics develops antibodies for immuno-oncology, "tuning" the immune system to fight cancer. The company's assets include scientific platforms and laboratories where these high-precision "weapons" are created. The chart shows the financial resources concentrated on this cutting-edge front in the fight against cancer.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Compass Therapeutics
Compass Therapeutics' balance sheet consists of cash in its accounts and the value of its lab equipment. The market, however, values the company's scientific platform for developing a new generation of antibodies to fight cancer, not its assets. The chart shows how much investors value this "science bet" over the company's tangible assets.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
Compass Therapeutics is a biotech company developing immuno-oncology drugs. Its value is entirely dependent on the success of its scientific research. This chart shows how its market valuation, which is a bet on future discoveries, relates to its current, mostly cash, balance sheet assets.
Market to book capitalization ratio for the market as a whole
Compass Therapeutics is a biotech company developing immuno-oncology drugs. Its value depends almost entirely on the potential success of its research and clinical trials. This chart shows how investors value its research portfolio, an example of a valuation based on future expectations rather than current assets.
Debts of the company, segment and market as a whole
CMPX - Company debts Compass Therapeutics
Compass Therapeutics, a biotech focused on immuno-oncology, is raising capital to fund its research. Debt instruments can be used to advance its drug candidates through early and mid-stage clinical trials. This chart reflects the company's financial strategy focused on scientific breakthroughs.
Market segment debts - Oncology immuno-therapy
Compass Therapeutics is a biotech company focused on developing immuno-oncology drugs. Financing lengthy and expensive clinical trials is a key challenge for such companies. This chart shows how Compass's debt load reflects the stage of development of its drug pipeline and its capital needs to continue research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Compass Therapeutics
Compass Therapeutics is another biotech company focused on immuno-oncology. Its path to success lies through expensive clinical trials. This chart shows the ratio of equity to debt in funding its research, clearly demonstrating the level of financial risk involved in developing breakthrough drugs.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
Compass Therapeutics, a biotech company developing immunotherapeutic drugs for cancer, compares its debt load to the overall market capitalization of the oncology sector. It shows how the clinical-stage company funds its research and development, which is critical to its future success.
Debt to book value of all companies in the market
Compass Therapeutics is a biopharmaceutical company focused on immuno-oncology. Developing innovative drugs requires long-term, risk-taking investments. This graph of total market debt reflects the risk appetite of the broader economy, providing important context for assessing the company's ability to attract funding for its breakthrough research.
P/E of the company, segment and market as a whole
P/E - Compass Therapeutics
This chart for Compass Therapeutics illustrates the complex task of valuing an early-stage biopharmaceutical company. The company is focused on developing immuno-oncology drugs. Because it lacks stable profitability, any formal metric reflects investors' speculative expectations regarding the success of its clinical trials rather than actual revenue.
P/E of the market segment - Oncology immuno-therapy
Compass Therapeutics is a biopharmaceutical company developing immuno-oncology drugs for the treatment of cancer. Its approach involves creating antibodies that stimulate the immune system to fight tumors. This chart illustrates the average valuation in the immuno-oncology sector, one of the most promising but also competitive areas in the pharmaceutical industry.
P/E of the market as a whole
Compass Therapeutics is a biotech company focused on developing immuno-oncology drugs. Its value depends on clinical trial success and the potential of its scientific platform. This chart shows the overall market temperature. Comparing it with it reveals how disconnected Compass's valuation is from market realities and relies solely on hopes for a scientific breakthrough.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Compass Therapeutics
For Compass Therapeutics, a biopharmaceutical company focused on immuno-oncology, this chart demonstrates market expectations for its future scientific and commercial success. It reflects investor confidence in the potential of the antibodies being developed for cancer treatment and their ability to generate significant revenue once approved and marketed.
%20P%2FE%20Compass%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Compass-Therapeutics&v=1772513426890 "Chart of the company's future (projected) P/E Compass Therapeutics")
Future (projected) P/E of the market segment - Oncology immuno-therapy
Compass Therapeutics develops immuno-oncology antibodies for the treatment of cancer. The data presented here serves as an indicator of expectations for the entire biotech segment. The position of the CMPX relative to the average may indicate how highly the market values the scientific potential of its developments in this highly competitive and promising field.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772513426904 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
Compass Therapeutics is at the forefront of immuno-oncology. For a company without stable revenue, the overall market valuation shown in this chart is of secondary importance. Scientific progress is paramount. However, high market optimism facilitates fundraising for further research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513426931 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Compass Therapeutics
Compass Therapeutics is a biopharmaceutical company focused on developing immuno-oncology drugs. This chart illustrates the stages of cancer drug development. Periods of loss are due to massive investments in R&D, while potential sharp profit increases depend on the success of clinical trials and partnerships with major pharmaceutical companies.
Profit of companies in the market segment - Oncology immuno-therapy
Compass Therapeutics develops immunotherapeutic drugs for cancer treatment by targeting the tumor microenvironment. The profitability chart of this niche biotech segment demonstrates the collective bet of investors on scientific breakthroughs. The success of CMPX and its industry peers depends on the results of clinical trials, which can make or break the entire sector.
Overall market profit
Compass Therapeutics, focused on immuno-oncology, is at the forefront of biotech, where success depends on scientific breakthroughs rather than the current economic cycle. However, the overall market environment, reflected in the chart, influences the availability of venture capital and the willingness of large pharmaceutical companies to partner, which is critical for funding their research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Compass Therapeutics
Compass Therapeutics is at the forefront of immuno-oncology, and its future value is priced into the potential of its drugs. This chart shows analysts' estimates of the likelihood of clinical trial success and subsequent commercialization. It represents the financial expression of the company's hopes that its developments will lead to a breakthrough in cancer treatment.
%20profit%20of%20the%20company%20Compass%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Compass-Therapeutics&v=1772513426960 "Graph of future (projected) profit of the company Compass Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
Compass Therapeutics develops immuno-oncology antibodies for the treatment of cancer. The company's prospects depend entirely on breakthrough scientific research and clinical confirmation. This chart illustrates overall profitability expectations in the immuno-oncology segment, reflecting the market's confidence in the potential of this cutting-edge approach to cancer treatment.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772513427017 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
Compass Therapeutics is a biopharmaceutical company focused on immuno-oncology. Like many development-stage biotechs, its shares react less to general economic forecasts than to news about clinical trials. However, the overall market sentiment, reflected in the chart, influences the cost and availability of capital needed to continue research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513427048 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Compass Therapeutics
Compass Therapeutics develops innovative immuno-oncology drugs targeting cancer. While in clinical trials, the company generates limited revenue from partnerships. The chart shows how the market values these early revenues, factoring in the enormous potential of its scientific developments and future blockbusters.
P/S market segment - Oncology immuno-therapy
Compass Therapeutics develops antibodies for immuno-oncology, aiming to stimulate the immune system to fight cancer. The chart shows the average revenue estimate for biotech companies. It helps assess whether investor expectations for the scientific potential of Compass's platform are higher or lower than the average for the innovation sector.
P/S of the market as a whole
Compass Therapeutics develops immunotherapeutic drugs for the treatment of oncology. This is a high-risk, high-potential field. The chart showing the average market revenue estimate serves as a benchmark for understanding the blockbuster expectations investors are factoring into the company's current valuation.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Compass Therapeutics
Compass Therapeutics is a biotech company developing a new generation of cancer immunotherapy drugs. Like many companies in this field, its valuation is a bet on a future breakthrough. The chart shows how the market values its scientific platform relative to the potentially huge future revenues from its innovative drugs.
%20P%2FS%20Compass%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Compass-Therapeutics&v=1772513427309 "The graph of the company's future (projected) P/S Compass Therapeutics")
Future (projected) P/S of the market segment - Oncology immuno-therapy
Compass Therapeutics develops antibodies for cancer immunotherapy targeting complex targets. The chart illustrates average future sales expectations for companies in this cutting-edge field. It helps investors understand how the market values Compass's scientific platform and drug candidates compared to those of other immuno-oncology companies.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772513427340 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
Compass Therapeutics, a biopharmaceutical company, is in a sector where expectations are driven not by economic cycles but by scientific discoveries. This chart shows a general belief in sales growth. However, CMPX investors are not looking at this chart, but at the results of immuno-oncology research, which could lead to a blockbuster and exponential revenue growth.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513427356 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Compass Therapeutics
Compass Therapeutics is a biotech company focused on developing immunotherapies for cancer treatment. While in clinical trials, the company does not yet have revenue from sales of finished products. The metrics in this chart typically reflect revenue from strategic partnerships, which are critical for funding development.
Sales of companies in the market segment - Oncology immuno-therapy
Compass Therapeutics is a biopharmaceutical company focused on developing immuno-oncology therapeutics. It develops antibodies that stimulate the patient's immune system to fight cancer cells, offering new treatment approaches. This chart shows the total revenue for the entire segment, allowing one to assess the rapid growth and commercialization of the immunotherapy market.
Overall market sales
Compass Therapeutics develops immuno-oncology drugs to combat cancer. This chart reflects the state of the economy, but other metrics are important for CMPX: clinical trial data and regulatory decisions. Breakthroughs in treating serious diseases create value regardless of market conditions, making the biotech sector a unique world of innovation.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Compass Therapeutics
Compass Therapeutics develops innovative immuno-oncology drugs for the treatment of cancer. The company's future depends entirely on the results of clinical trials and potential approval of its therapies. This chart visualizes investor and analyst expectations regarding the company's scientific and commercial breakthroughs.
%20sales%20of%20the%20company%20Compass%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Compass-Therapeutics&v=1772513427625 "Schedule of future (projected) sales of the company Compass Therapeutics")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
Compass Therapeutics develops innovative antibodies for cancer immunotherapy. The company operates at the cutting edge of science, where every successful drug can be a game-changer. This chart illustrates forecasts for the entire immuno-oncology sector. Compass's success depends on whether their scientific approach can be translated into a commercially viable product.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772513427637 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
Compass Therapeutics develops immuno-oncology drugs. The company is sensitive to the overall economic environment, as illustrated by this chart. Stable economic growth ensures capital flows into risky biotech projects and ensures the future solvency of healthcare systems, which is key to successfully bringing new drugs to market.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513427647 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Compass Therapeutics
Compass Therapeutics is a biotech company focused on developing next-generation cancer immunotherapy drugs. Like many companies in clinical trials, it incurs significant R&D expenses. This chart illustrates the history of investing in the future of medicine, where today's costs are the foundation for tomorrow's potential profitability.
Market segment marginality - Oncology immuno-therapy
Compass Therapeutics is a biopharmaceutical company developing immunotherapeutic drugs for the treatment of oncology. This chart shows the average revenue in the pharmaceutical industry. As a clinical-stage company, its future ability to exceed this metric depends entirely on the success of its development pipeline and partnerships with major pharmaceutical companies.
Market marginality as a whole
Compass Therapeutics is developing immunotherapeutic antibodies for the treatment of oncology. The company is in the research stage, and its current financial metrics reflect expenses, not revenue. This total profitability chart highlights how different the advanced biopharmaceutical business is from traditional models focused on operating margins.
Employees in the company, segment and market as a whole
Number of employees in the company Compass Therapeutics
For Compass Therapeutics, which develops immuno-oncology drugs, this chart reflects research activity. The increasing indicator indicates that the company is simultaneously advancing several drug candidates through preclinical and clinical trials, demonstrating the maturity and breadth of its scientific portfolio.
Share of the company's employees Compass Therapeutics within the market segment - Oncology immuno-therapy
Compass Therapeutics is exploring new avenues for cancer treatment by developing immuno-oncology drugs. This field is highly competitive for the best minds. This metric reflects the percentage of the scientific community a company attracts in its niche field. This allows investors to assess its potential not only by its patents but also by the concentration of talent capable of making breakthroughs.
Number of employees in the market segment - Oncology immuno-therapy
Compass Therapeutics is a biopharmaceutical company developing immuno-oncology drugs. The headcount chart illustrates the progress of research. The growth of the team of scientists and clinicians often coincides with the advancement of promising drug candidates to later, more expensive stages of clinical trials.
Number of employees in the market as a whole
Compass Therapeutics develops immuno-oncology drugs. Its operations operate outside the traditional economic cycles shown in this chart. The company's success depends on scientific breakthroughs and regulatory approvals. The need for effective cancer treatments is always present, regardless of the labor market.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Compass Therapeutics (CMPX)
Compass Therapeutics is a biotech company whose value is locked into its pipeline of potential drugs. This chart clearly demonstrates how the market values science over human capital. The company's entire market capitalization is based on the success of its research, conducted by a small team, leading to a very high valuation per employee.
%20of%20the%20company%20Compass%20Therapeutics%20(CMPX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Compass-Therapeutics-CMPX&v=1772513427895 "Chart of market capitalization per employee (in thousands of dollars) of the company Compass Therapeutics (CMPX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Compass Therapeutics develops innovative immuno-oncology drugs. Like many biotechs in the R&D stage, its value is determined by the prospects of scientific discoveries, not by current operations or staff. This chart shows how investors evaluate the company's potential per member of its scientific team.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772513427908 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Compass Therapeutics is a biotech company developing antibodies for cancer immunotherapy. Its entire capital comes from its scientific potential. The chart illustrates the market valuation of research and development. It shows how highly investors value the contribution of a small team of scientists to the development of potentially breakthrough drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513427925 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Compass Therapeutics (CMPX)
Compass Therapeutics is a biopharmaceutical company specializing in immuno-oncology. They are developing antibodies to fight cancer. This chart shows a classic picture of biotech R&D. It reflects how much capital is invested (or "burned") per scientist working on the next generation of drugs. This is a measure of investment in intellectual capital.
%20Chart%20Compass%20Therapeutics%20(CMPX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Compass-Therapeutics-CMPX&v=1772513427994 "Company Profit Per Employee (in thousands of dollars) Chart Compass Therapeutics (CMPX)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Compass Therapeutics (CMPX) is an R&D biotech (immuno-oncology). This chart shows the benchmark for "Immuno-oncology" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of cash in the hopes of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772513428007 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Compass Therapeutics is a clinical-stage biotech developing cancer immunotherapy. Like many R&D companies, CMPX has no commercial products yet and, therefore, no profit. This chart reflects the burn rate of capital spent on research. It shows the loss per scientist, which is typical for breakthrough drug discovery.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513428073 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Compass Therapeutics (CMPX)
Compass Therapeutics works in the field of immuno-oncology. For a biopharmaceutical company in the research stage, this chart is especially important. The emergence and growth of revenue per employee signals a key milestone: the successful commercialization of developments through partnerships or licensing deals, where each scientist's contribution is monetized.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Compass-Therapeutics-CMPX&v=1772513428102 "Sales chart per company employee Compass Therapeutics (CMPX)")
Sales per employee in the market segment - Oncology immuno-therapy
Compass Therapeutics (CMPX) is a clinical-stage biopharmaceutical company focused on immuno-oncology. Like most biotechs without an approved product, CMPX has no commercial revenue. On this chart, their revenue would be close to zero. While revenue is only relevant for commercial companies, investors at CMPX focus on the development potential.
Sales per employee for the market as a whole
Compass Therapeutics is an immuno-oncology company. Like many development-stage biotechs, this metric reflects ongoing investment in research. A team of highly qualified researchers is working on future drugs. This graph is important for tracking the transition to commercialization, when revenue from approved drugs begins to cover the cost of R&D personnel.
Short shares by company, segment and market as a whole
Shares shorted by company Compass Therapeutics (CMPX)
Compass Therapeutics (CMPX) is a biopharmaceutical company developing immuno-oncology drugs. They are looking for ways to "unleash" a patient's own immune system against cancer cells. This chart reflects bearish bets. The high number of skeptics could indicate doubts about the success of their clinical trials or intense competition in this field.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Compass-Therapeutics-CMPX&v=1772513428230 "Short Shares Chart for the Company Compass Therapeutics (CMPX)")
Shares shorted by market segment - Oncology immuno-therapy
Compass Therapeutics (CMPX) is a clinical-stage biotech developing immunotherapies for cancer (checkpoint inhibitors). This chart is a barometer of sentiment across the entire biotech industry. If investors are shorting the sector, they don't believe risky R&D in this highly competitive field will succeed. For CMPX, this signals a "venture drought" for funding trials.
Shares shorted by the overall market
Compass Therapeutics (CMPX) is a clinical-stage biotech developing antibodies for immuno-oncology. This chart reflects overall market pessimism. When investors are fearful (the indicator rises), they flee en masse from speculative biotechs that lack profitability. CMPX shares can fall simply due to risk-off sentiment, regardless of their scientific developments.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Compass Therapeutics (CMPX)
Compass Therapeutics is a biotech company focused on immuno-oncology. This chart measures the extremes of speculative sentiment. It shows when the stock is "overheated" (overbought) on positive lab news or "oversold" (bottomed out) amid a general cooling in the biotech sector or a setback.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Compass-Therapeutics-CMPX&v=1772513428266 "RSI 14 indicator chart for the company's stock Compass Therapeutics (CMPX)")
RSI 14 Market Segment - Oncology immuno-therapy
Compass Therapeutics is a biotech company focused on immuno-oncology. They develop antibodies (including bispecific ones) that target multiple immune system activation pathways against cancer. This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire segment is overheated.
RSI 14 for the overall market
Compass Therapeutics (CMPX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CMPX (Compass Therapeutics)
Compass Therapeutics is a biotech company developing a new generation of immuno-oncology drugs aimed at stimulating the immune system to fight cancer. This chart shows the average price forecast by analysts. Their targets are based on early clinical trial data and the potential of their platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CMPX-Compass-Therapeutics&v=1772513428309 "A chart showing analyst consensus forecasts for the expected stock price. CMPX (Compass Therapeutics)")
The difference between the consensus estimate and the actual stock price CMPX (Compass Therapeutics)
Compass Therapeutics is a clinical-stage biotech focused on immuno-oncology. They are developing bispecific antibodies that aim to simultaneously attack multiple cancer targets. This chart reflects analysts' speculative expectations regarding their R&D platform and the chances of success in early clinical trials. It shows the gap between their target price and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CMPX-Compass-Therapeutics&v=1772513428349 "A chart showing the difference between the consensus forecast and the actual stock price. CMPX (Compass Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
Compass Therapeutics is a biotech company developing a new generation of cancer immunotherapy (bispecific antibodies). This is cutting-edge, yet risky, R&D. This chart shows analysts' overall expectations for the entire immunotherapy sector. It reflects whether experts believe new breakthroughs in cancer treatment are possible or whether they consider the sector overheated.
Analysts' consensus forecast for the overall market share price
Compass Therapeutics is a clinical-stage biotech focused on developing next-generation immuno-oncology therapeutics. Like many biotechs, their valuation is based on future expectations. This chart shows the overall market risk appetite. Analyst optimism (rising chart) is critical for funding such long-term research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Compass Therapeutics
Compass Therapeutics is a biotech company working in the field of immuno-oncology. They are developing bispecific antibodies that aim to target the immune system against cancer cells more effectively than existing drugs. This graph is a pure assessment of their R&D pipeline. Its dynamics depend entirely on their progress in clinical trials and the market's confidence in their scientific platform.
AKIMA Market Segment Index - Oncology immuno-therapy
Compass Therapeutics is a biotech company specializing in the new frontier of immuno-oncology, developing novel antibodies to stimulate the immune system against cancer. The chart shows the average value for the entire biotech segment. This average serves as a benchmark. It helps investors assess whether Compass's scientific platform appears more promising than that of a typical competitor.
The AKIM Index for the overall market
Compass Therapeutics is a biotech company developing antibodies to treat cancer by modulating the immune system. This chart, which reflects the market average, is a risk appetite indicator. It provides a macro backdrop that is critical for assessing how the market views scientific prospects relative to overall volatility.
